Alpha 2.0
Login Register
» Authors » Takashi Higuchi

Takashi Higuchi

Explore the profile of Takashi Higuchi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 256
Citations 1824
Followers 0
Related Specialties
Oncology
Biochemistry
Science
Top 10 Co-Authors
Hiroyuki Tsuchiya
Norio Yamamoto
Katsuhiro Hayashi
Shinji Miwa
Kentaro Igarashi
Robert M Hoffman
Hiroaki Kimura
Akihiko Takeuchi
Michael Bouvet
Yuta Taniguchi
Published In
Anticancer Res
Mol Genet Metab
Biochem Biophys Res Commun
BMC Musculoskelet Disord
Sci Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
Highly Synergistic Eradication of 143B Osteosarcoma Cells by the Combination of Recombinant Methioninase, Chloroquine, and Rapamycin Targeting Methionine Addiction, Autophagy, and mTOR, Respectively
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
Anticancer Res . 2025 Mar; 45(3):935-941. PMID: 40037880
Background/aim: Drug-resistant osteosarcoma is a highly aggressive malignancy with limited therapeutic options. Recombinant methioninase (rMETase) targets the methionine addiction of cancer and acts synergistically with many cancer-chemotherapy agents. The present...
2.
HT1080 Fibrosarcoma With Acquired Trabectedin Resistance: Increased Malignancy But Sustained Sensitivity to Methionine Restriction
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
In Vivo . 2025 Feb; 39(2):683-690. PMID: 40010975
Background/aim: Trabectedin is a DNA-binding agent that has shown moderate efficacy for soft-tissue sarcomas. We have previously shown that methionine restriction enhances trabectedin efficacy on both parental and trabectedin-resistant HT1080...
3.
Dynamic Fluorescence Imaging of Orally-administered Tumor-targeting A1-R Expressing Green Fluorescent Protein Trafficking Through the Gastrointestinal System to Target Fibrosarcomas in Nude Mice
Morinaga S, Zhao M, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
In Vivo . 2025 Feb; 39(2):640-647. PMID: 40010967
Background/aim: A1-R (A1-R) expresses green fluorescent protein (GFP) and has the ability to selectively target and inhibit all major cancer types in murine models without persistently infecting healthy tissue. A1-R...
4.
Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin
Morinaga S, Han Q, Mizuta K, Kang B, Hozumi C, Bouvet M, et al.
Anticancer Res . 2025 Jan; 45(2):451-455. PMID: 39890170
Background/aim: Ivermectin is a widely-used anti-parasitic agent and has shown early promise as an anticancer agent. Recombinant methioninase (rMETase) is a methionine-depleting enzyme targeting the methionine addiction of cancer and...
5.
Prostate Cancer Patient With Lymph-node Metastasis Treated Only With Methionine Restriction Has Stable Disease for Two Years Demonstrated With PET/CT and PSMA-PET Scanning and PSA Testing
Morinaga S, Han Q, Mizuta K, Kang B, Yamamoto N, Hayashi K, et al.
Cancer Diagn Progn . 2025 Jan; 5(1):27-31. PMID: 39758238
Background/aim: Metastatic prostate cancer is a recalcitrant disease. Our laboratory has previously treated prostate-cancer patients with methionine restriction effected by a low methionine diet and oral recombinant methioninase (o-rMETase), both...
6.
Elevated-c-MYC-expressing Fibrosarcoma Cells With Acquired Gemcitabine Resistance Remain Sensitive to Recombinant Methioninase: A Potential Clinical Strategy for a Recalcitrant Disease
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
Cancer Diagn Progn . 2025 Jan; 5(1):8-14. PMID: 39758233
Background/aim: For second-line chemotherapy of soft-tissue sarcoma, gemcitabine is administered in combination with docetaxel. However, more effective treatments are required for advanced soft-tissue sarcoma, where the efficacy is limited. The...
7.
Complete Response (CR) in a Previously-progressing Chronic Lymphocytic Leukemia (CLL) Patient Treated With Methionine Restriction in Combination With First-line Chemotherapy
Morinaga S, Han Q, Mizuta K, Kang B, Yamamoto N, Hayashi K, et al.
Cancer Diagn Progn . 2025 Jan; 5(1):21-26. PMID: 39758229
Background/aim: Chronic lymphocytic leukemia (CLL) is currently incurable. CLL is characterized by disordered DNA methylation. The aim of the present study was to target methylation with methionine restriction in a...
8.
Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse Models
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
In Vivo . 2024 Dec; 39(1):120-126. PMID: 39740911
Background/aim: Ifosfamide is used clinically with doxorubicin as first-line chemotherapy for soft-tissue sarcoma. However, ifosfamide efficacy for soft-tissue sarcoma is limited due to frequent occurence of ifosfamide resistance and thus...
9.
The Combination of Tumor-targeting A1-R Plus the Autophagy-inhibitor Chloroquine Synergistically Eradicates HT1080 Fibrosarcoma Cells and
Morinaga S, Zhao M, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
In Vivo . 2024 Dec; 39(1):102-109. PMID: 39740880
Background/aim: Salmonella typhimurium A1-R (A1-R) targets and inhibits a wide range of cancer types without continuously infecting healthy tissue. Chloroquine, an antimalarial drug, induces apoptosis and inhibits autophagy in cancer...
10.
Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells
Morinaga S, Han Q, Mizuta K, Kang B, Bouvet M, Yamamoto N, et al.
Anticancer Res . 2024 Dec; 45(1):97-103. PMID: 39740811
Background/aim: Ivermectin was initially utilized as a veterinary medication, demonstrating efficacy against various parasites. Pancreatic cancer is currently one of the most recalcitrant diseases. The aim of the present study...